Focus on Oral, Head, Neck & Thyroid Cancers
The U.S. Food and Drug Administration has expanded the approved uses of Nexavar (sorafenib) to treat late-stage (metastatic) differentiated thyroid cancer. The drug’s new use is intended for patients with locally recurrent or metastatic, progressive differentiated thyroid cancer that no longer responds to radioactive iodine treatment.
The FDA completed review of Cometriq’s application in six months under the agency’s priority review program. This program provides for an expedited six-month review for drugs that may offer major advances in treatment or that provide a treatment when no adequate therapy exists. Cometriq also received orphan-product designation by the FDA because it is intended to treat a rare disease or condition.
The Oral Cancer Foundation is a national nonprofit organization designed for advocacy and service, created to promote change and save lives through prevention, education, research, and patient support. Approximately 37,000 people in the U.S. will be diagnosed with oral cancer this year.